Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page loses the 'Melanoma' condition tag, the 'related topics:' section header, and the MedlinePlus Genetics link, altering how the study's disease focus and related resources are presented on the page.
    Difference
    0.2%
    Check dated 2026-08-25T16:35:21.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision: v3.6.5 was added, replacing v3.6.4, indicating a minor update to the page system without altering study information.
    Difference
    0.1%
    Check dated 2026-08-11T05:51:50.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.6.4 was added and Revision: v3.6.3 was removed, updating the page's version label.
    Difference
    0.1%
    Check dated 2026-07-28T03:13:29.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.2 to v3.6.3. This reflects an internal update to the page's revision history and does not affect the visible trial information.
    Difference
    0.1%
    Check dated 2026-07-06T16:32:38.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page revision identifier was updated from v3.6.0 to v3.6.2, indicating a minor update to the study record. No substantive content changes are indicated.
    Difference
    0.1%
    Check dated 2026-06-29T08:31:07.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The study page now indicates that recruitment is closed, reflecting that no further participants will be enrolled. This helps users understand that enrollment has ended and to adjust expectations accordingly.
    Difference
    0.8%
    Check dated 2026-06-15T05:52:47.000Z thumbnail image

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.